Stuart Johnasha D, Salinas Eduardo, Grakoui Arash
Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, United States.
Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, United States; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Curr Opin Virol. 2021 Feb;46:36-44. doi: 10.1016/j.coviro.2020.10.002. Epub 2020 Nov 1.
Hepatitis C virus (HCV) remains a global public health problem even though more than 95% of infections can be cured by treatment with direct-acting antiviral agents. Resolution of viremia post antiviral therapy does not lead to protective immunity and therefore reinfections can occur. Immune cell detection of HCV activates signaling pathways that produce interferons and trigger the innate immune response against the virus, preventing HCV replication and spread. Cells in the innate immune system, including natural killer, dendritic, and Kupffer cells, interact with infected hepatocytes and present viral antigens to T and B cells where their effector responses contribute to infection outcome. Despite the immune activation, HCV can evade the host response and establish persistent infection. Plans to understand the correlates of protection and strategies to activate proper innate and adaptive immune responses are needed for development of an effective prophylactic vaccine that stimulates protective immunity and limits HCV transmission.
丙型肝炎病毒(HCV)仍然是一个全球性的公共卫生问题,尽管超过95%的感染可以通过使用直接作用抗病毒药物治愈。抗病毒治疗后病毒血症的消除不会产生保护性免疫,因此可能会再次感染。HCV的免疫细胞检测激活产生干扰素的信号通路,并触发针对该病毒的固有免疫反应,从而防止HCV复制和传播。固有免疫系统中的细胞,包括自然杀伤细胞、树突状细胞和库普弗细胞,与受感染的肝细胞相互作用,并将病毒抗原呈递给T细胞和B细胞,它们的效应反应有助于感染结果。尽管有免疫激活,但HCV仍可逃避宿主反应并建立持续感染。为了开发一种有效的预防性疫苗,刺激保护性免疫并限制HCV传播,需要制定了解保护相关性的计划以及激活适当的固有和适应性免疫反应的策略。